Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations in glioblastoma proteins do not disrupt epitope presentation and recognition, maintaining a specific CD8 T cell immune response potential.

Scientific reports - 19 Jul 2024

Tarabini Renata Fioravanti, Fioravanti Vieira Gustavo, Rigo Maurício Menegatti, de Souza Ana Paula Duarte

Abstract excerpt

Antigen-specific cytotoxic CD8 T cells are extremely effective in controlling tumor growth and have been the focus of immunotherapy approaches. We leverage in silico tools to investigate whether the occurrence of mutations in proteins previously described as immunogenic and highly expressed by glioblastoma multiforme (GBM), such as Epidermal Growth Factor Receptor (EGFR), Isocitrate Dehydrogenase 1 (IDH1),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigen Presentation
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD8-Positive T-Lymphocytes

Share to Epitopes, T-Lymphocyte

Share to Glioblastoma

Share to Histocompatibility Antigens Class I

Share to Isocitrate Dehydrogenase

Share to PTEN Phosphohydrolase

Source

Open in PubMed Open full text

Identifiers

PMID: 39030304
DOI: 10.1038/s41598-024-67099-2
PMCID: PMC11271619

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations in glioblastoma proteins do not disrupt epitope presentation and recognition, maintaining a specific CD8 T cell immune response potential.PMID 39030304Read ↗

CTL recognition of a novel HLA-A*0201-binding peptide derived from glioblastoma multiforme tumor cells.Semantic proximity Read ↗

Identification and prioritisation of tumour antigen candidates from 79 glioblastoma transcriptomes.Semantic proximity Read ↗

Cancer missense mutations alter binding properties of proteins and their interaction networks.Semantic proximity Read ↗

The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA allelesSemantic proximity Read ↗

A Computational Pipeline for Glioblastoma Vaccine Development: Integrating Novel Omics-Driven OIP5 Target Discovery to Create a Deep Learning-Based Immunogenicity Framework for Personalized ImmunotherapySemantic proximity Read ↗

AI-driven structural analysis clarifies novel TNFRSF17 variants of uncertain significance as drivers of resistance to BCMA-targeted immunotherapies in multiple myelomaSemantic proximity Read ↗

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.Semantic proximity Read ↗

Molecular mechanism of phosphopeptide neoantigen immunogenicitySemantic proximity Read ↗

The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles.Semantic proximity Read ↗

Low immunogenicity of common cancer hot spot mutations resulting in false immunogenic selection signals.Semantic proximity Read ↗

Cancers modulate p53 truncal neoantigen display to evade T cell detectionSemantic proximity Read ↗

In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.